Immunotherapy for melanoma

Cancer Control

Volumn 9, Issue 1, 2002, Pages 22-30

  Kim, Christina J ^a   Dessureault, Sophie ^a   Gabrilovich, Dimitry ^a   Reintgen, Douglas S ^a   Slingluff Jr , Craig L ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CYTOKINE; DNA; MELANOMA VACCINE; PEPTIDE; RNA; CANCER VACCINE;

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; MELANOMA; REVIEW; TUMOR CELL; ACTIVE IMMUNIZATION; CONTROLLED CLINICAL TRIAL; FEMALE; IMMUNOTHERAPY; MALE; METHODOLOGY; MORTALITY; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SKIN TUMOR; SURVIVAL; TREATMENT OUTCOME;

CANCER VACCINES; CONTROLLED CLINICAL TRIALS; FEMALE; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; MALE; MELANOMA; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036194868     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480200900104     Document Type: Review

References (84)

1. Cutaneous melanoma
2. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
3. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
4. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
5. Principles of cancer management: Biologic therapy
6. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
7. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
8. A review of the influence of bacterial infection and of bacterial products (Coley's toxin) on malignant tumors in man
9. Mechanism of action of BCG-tumor cell vaccines in the generation of systemic tumor immunity. II. Influence of the local inflammatory response on immune reactivity
10. Inhibition of tumour growth by administration of killed Corynebacterium parvum
11. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes: Evidence for shared tumor antigens
12. Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens
13. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides
14. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results and possible mechanisms of action
15. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients
16. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma
17. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma
18. Induction of primary NY-ESO-1 immunity: CD8+T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
19. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients
20. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801
21. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development
22. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel pathway for processing of membrane proteins
23. Two tyrosinase nonpeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes
24. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes
25. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes
26. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
27. Identification of a novel peptide derived from the melanocyte-specific gp l00 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line
28. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
29. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
30. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
31. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100
32. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells
33. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles
34. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
35. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
36. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes
37. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes
38. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)
39. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
40. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33
41. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
42. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
43. Generation of xenogeneic cytotoxic T cells from peptides derived from the her-2/neu protooncogene
44. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer
45. Ovarian and breast tumor associated T lymphocytes stimulated with an antigenic peptide derived from her2/neu show enhanced cytotoxicity against autologous tumor
46. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide
47. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer
48. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides
49. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
50. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1
51. Antologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601
52. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product
53. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
54. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3
55. Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3
56. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3
57. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes
58. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma
59. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene
60. Simultaneous humoral and cellular immune response against cancer-testis antigen NYESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
61. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames
62. A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients
63. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes
64. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
65. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene
66. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma
67. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma
68. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1
69. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
70. Melanoma vaccines: Any evidence that they actually work?
71. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer
72. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and antologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma
73. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor imnunity
74. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
75. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
76. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
77. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma
78. Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma- associated antigens MART-1 and gp100
79. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells
80. Exposing the immunology of naked DNA vaccines
81. Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gp100/pme117
82. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce anti-tumor immunity against central nervous system tumors
83. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
84. Melanoma vaccine momentum spurs interest, investment